BIOVF
Price
$30.75
Change
+$1.78 (+6.14%)
Updated
Aug 22 closing price
Capitalization
10.4B
BOIRF
Price
$24.30
Change
+$0.30 (+1.25%)
Updated
Aug 14 closing price
Capitalization
431.52M
Interact to see
Advertisement

BIOVF vs BOIRF

Header iconBIOVF vs BOIRF Comparison
Open Charts BIOVF vs BOIRFBanner chart's image
Swedish Orphan Biovitrum AB
Price$30.75
Change+$1.78 (+6.14%)
Volume$243
Capitalization10.4B
Boiron
Price$24.30
Change+$0.30 (+1.25%)
Volume$300
Capitalization431.52M
BIOVF vs BOIRF Comparison Chart in %
Loading...
BIOVF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BOIRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIOVF vs. BOIRF commentary
Aug 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOVF is a StrongBuy and BOIRF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 28, 2025
Stock price -- (BIOVF: $30.75 vs. BOIRF: $24.30)
Brand notoriety: BIOVF and BOIRF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BIOVF: 80% vs. BOIRF: 132%
Market capitalization -- BIOVF: $10.4B vs. BOIRF: $431.52M
BIOVF [@Pharmaceuticals: Generic] is valued at $10.4B. BOIRF’s [@Pharmaceuticals: Generic] market capitalization is $431.52M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.86B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIOVF’s FA Score shows that 0 FA rating(s) are green whileBOIRF’s FA Score has 2 green FA rating(s).

  • BIOVF’s FA Score: 0 green, 5 red.
  • BOIRF’s FA Score: 2 green, 3 red.
According to our system of comparison, BOIRF is a better buy in the long-term than BIOVF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIOVF’s TA Score shows that 5 TA indicator(s) are bullish while BOIRF’s TA Score has 2 bullish TA indicator(s).

  • BIOVF’s TA Score: 5 bullish, 3 bearish.
  • BOIRF’s TA Score: 2 bullish, 3 bearish.
According to our system of comparison, BIOVF is a better buy in the short-term than BOIRF.

Price Growth

BIOVF (@Pharmaceuticals: Generic) experienced а +6.14% price change this week, while BOIRF (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.10%. For the same industry, the average monthly price growth was +11.51%, and the average quarterly price growth was +89.56%.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIOVF($10.4B) has a higher market cap than BOIRF($432M). BOIRF has higher P/E ratio than BIOVF: BOIRF (32.19) vs BIOVF (23.39). BIOVF YTD gains are higher at: 11.171 vs. BOIRF (-14.737).
BIOVFBOIRFBIOVF / BOIRF
Capitalization10.4B432M2,407%
EBITDA9.77BN/A-
Gain YTD11.171-14.737-76%
P/E Ratio23.3932.1973%
Revenue27BN/A-
Total Cash1.06BN/A-
Total Debt12.8BN/A-
FUNDAMENTALS RATINGS
BIOVF vs BOIRF: Fundamental Ratings
BIOVF
BOIRF
OUTLOOK RATING
1..100
9496
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
7
Undervalued
PROFIT vs RISK RATING
1..100
49100
SMR RATING
1..100
6570
PRICE GROWTH RATING
1..100
5285
P/E GROWTH RATING
1..100
919
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BOIRF's Valuation (7) in the null industry is significantly better than the same rating for BIOVF (80). This means that BOIRF’s stock grew significantly faster than BIOVF’s over the last 12 months.

BIOVF's Profit vs Risk Rating (49) in the null industry is somewhat better than the same rating for BOIRF (100). This means that BIOVF’s stock grew somewhat faster than BOIRF’s over the last 12 months.

BIOVF's SMR Rating (65) in the null industry is in the same range as BOIRF (70). This means that BIOVF’s stock grew similarly to BOIRF’s over the last 12 months.

BIOVF's Price Growth Rating (52) in the null industry is somewhat better than the same rating for BOIRF (85). This means that BIOVF’s stock grew somewhat faster than BOIRF’s over the last 12 months.

BOIRF's P/E Growth Rating (9) in the null industry is significantly better than the same rating for BIOVF (91). This means that BOIRF’s stock grew significantly faster than BIOVF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOVFBOIRF
RSI
ODDS (%)
Bearish Trend 2 days ago
52%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
29%
Momentum
ODDS (%)
Bullish Trend 2 days ago
49%
Bullish Trend 2 days ago
6%
MACD
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
7%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
47%
Bullish Trend 2 days ago
11%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
44%
Bearish Trend 2 days ago
29%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
48%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
58%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BIOVF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BOIRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JPUS122.950.53
+0.43%
JPMorgan Diversified Return US Eq ETF
SPYX53.220.12
+0.22%
SPDR® S&P 500 Fossil Fuel Rsrv Free ETF
HTAX23.470.03
+0.11%
Macquarie National High-Yield Municipal Bond ETF
TBX28.22-0.04
-0.14%
ProShares Short 7-10 Year Treasury
MFEM21.69-0.12
-0.55%
PIMCO RAFI Dyn Mlt-Fctr Emrg Mkts Eq ETF

BIOVF and

Correlation & Price change

A.I.dvisor tells us that BIOVF and INNPF have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOVF and INNPF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOVF
1D Price
Change %
BIOVF100%
N/A
INNPF - BIOVF
20%
Poorly correlated
+0.25%
APNHY - BIOVF
19%
Poorly correlated
+7.75%
BIOGY - BIOVF
11%
Poorly correlated
N/A
BOIRF - BIOVF
1%
Poorly correlated
N/A
ARSUF - BIOVF
1%
Poorly correlated
N/A
More

BOIRF and

Correlation & Price change

A.I.dvisor tells us that BOIRF and ELAN have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BOIRF and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BOIRF
1D Price
Change %
BOIRF100%
N/A
ELAN - BOIRF
21%
Poorly correlated
+3.30%
BUDZ - BOIRF
7%
Poorly correlated
+1.67%
BSPK - BOIRF
4%
Poorly correlated
N/A
APNHY - BOIRF
3%
Poorly correlated
+7.75%
BIOVF - BOIRF
1%
Poorly correlated
N/A
More